vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and INTERGROUP CORP (INTG). Click either name above to swap in a different company.
INTERGROUP CORP is the larger business by last-quarter revenue ($17.3M vs $16.1M, roughly 1.1× Journey Medical Corp). INTERGROUP CORP runs the higher net margin — 8.8% vs -7.8%, a 16.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 19.8%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 7.8%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.
DERM vs INTG — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $17.3M |
| Net Profit | $-1.2M | $1.5M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 11.6% |
| Net Margin | -7.8% | 8.8% |
| Revenue YoY | 27.3% | 19.8% |
| Net Profit YoY | -182.0% | 155.6% |
| EPS (diluted) | $-0.04 | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $17.3M | ||
| Q3 25 | $17.0M | $17.9M | ||
| Q2 25 | $15.0M | $16.2M | ||
| Q1 25 | $13.1M | $16.8M | ||
| Q4 24 | $12.6M | $14.4M | ||
| Q3 24 | $14.6M | $16.9M | ||
| Q2 24 | $14.9M | $13.4M | ||
| Q1 24 | $13.0M | $14.9M |
| Q4 25 | $-1.2M | $1.5M | ||
| Q3 25 | $-2.3M | $-535.0K | ||
| Q2 25 | $-3.8M | $-2.2M | ||
| Q1 25 | $-4.1M | $-578.0K | ||
| Q4 24 | $1.5M | $-2.7M | ||
| Q3 24 | $-2.4M | $-398.0K | ||
| Q2 24 | $-3.4M | $-4.9M | ||
| Q1 24 | $-10.4M | $-3.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 11.6% | ||
| Q3 25 | -9.0% | 15.3% | ||
| Q2 25 | -19.2% | 8.1% | ||
| Q1 25 | -25.3% | 14.0% | ||
| Q4 24 | 17.7% | 5.9% | ||
| Q3 24 | -19.8% | 18.5% | ||
| Q2 24 | -19.7% | 3.7% | ||
| Q1 24 | -77.4% | 4.8% |
| Q4 25 | -7.8% | 8.8% | ||
| Q3 25 | -13.6% | -3.0% | ||
| Q2 25 | -25.3% | -13.9% | ||
| Q1 25 | -31.0% | -3.4% | ||
| Q4 24 | 12.1% | -18.9% | ||
| Q3 24 | -16.3% | -2.4% | ||
| Q2 24 | -22.6% | -36.7% | ||
| Q1 24 | -80.1% | -21.3% |
| Q4 25 | $-0.04 | $0.71 | ||
| Q3 25 | $-0.09 | $-0.25 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.18 | $-0.27 | ||
| Q4 24 | $0.10 | $-1.26 | ||
| Q3 24 | $-0.12 | $-0.18 | ||
| Q2 24 | $-0.17 | — | ||
| Q1 24 | $-0.53 | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $7.5M |
| Total DebtLower is stronger | $25.3M | $233.2M |
| Stockholders' EquityBook value | $31.9M | $-85.2M |
| Total Assets | $94.6M | $101.1M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $7.5M | ||
| Q3 25 | $24.9M | $6.0M | ||
| Q2 25 | $20.3M | $6.1M | ||
| Q1 25 | $21.1M | $4.8M | ||
| Q4 24 | $20.3M | $15.4M | ||
| Q3 24 | $22.5M | $12.2M | ||
| Q2 24 | $23.9M | $11.6M | ||
| Q1 24 | $24.1M | $19.5M |
| Q4 25 | $25.3M | $233.2M | ||
| Q3 25 | $25.2M | $237.8M | ||
| Q2 25 | $25.1M | $240.5M | ||
| Q1 25 | $25.0M | $241.5M | ||
| Q4 24 | $24.9M | $227.2M | ||
| Q3 24 | $19.8M | $218.1M | ||
| Q2 24 | $19.7M | $225.7M | ||
| Q1 24 | $14.7M | $225.0M |
| Q4 25 | $31.9M | $-85.2M | ||
| Q3 25 | $25.9M | $-86.7M | ||
| Q2 25 | $19.2M | $-86.1M | ||
| Q1 25 | $21.5M | $-84.5M | ||
| Q4 24 | $20.1M | $-83.9M | ||
| Q3 24 | $10.9M | $-80.9M | ||
| Q2 24 | $11.3M | $-80.3M | ||
| Q1 24 | $13.0M | $-76.4M |
| Q4 25 | $94.6M | $101.1M | ||
| Q3 25 | $85.2M | $102.5M | ||
| Q2 25 | $81.2M | $104.1M | ||
| Q1 25 | $85.0M | $103.2M | ||
| Q4 24 | $80.2M | $110.6M | ||
| Q3 24 | $64.0M | $109.3M | ||
| Q2 24 | $65.2M | $107.8M | ||
| Q1 24 | $66.6M | $119.0M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-23.0K |
| Free Cash FlowOCF − Capex | — | $-481.0K |
| FCF MarginFCF / Revenue | — | -2.8% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | — | -0.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | $739.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-23.0K | ||
| Q3 25 | $-2.4M | $-296.0K | ||
| Q2 25 | $-942.0K | $5.9M | ||
| Q1 25 | $-2.8M | $-854.0K | ||
| Q4 24 | $2.2M | $-781.0K | ||
| Q3 24 | $-1.2M | $3.4M | ||
| Q2 24 | $-5.2M | $6.8M | ||
| Q1 24 | $-5.0M | $1.9M |
| Q4 25 | — | $-481.0K | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | -7.1% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | -6.8% | ||
| Q4 24 | — | -7.8% | ||
| Q3 24 | — | 18.3% | ||
| Q2 24 | — | 20.4% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.6% | ||
| Q2 24 | — | 30.4% | ||
| Q1 24 | — | 4.9% |
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
INTG
| Hotel Operations | $12.7M | 73% |
| Real Estate Operation | $4.6M | 27% |
